Miragen Therapeutics this week announced that it has closed a $20 million Series B round of financing.
The financing was led by Remeditex Ventures with participation from Miragen's existing investor base, including Atlas Venture, Boulder Ventures, Amgen Ventures, and Broadview Ventures.
The company said the funding would be used to advance its pipeline of microRNA-based drugs.